ABRAMS: You are right that we do not want to see trials that a lot of time and effort has been put into, and patients have joined, and then don’t meet their enrollment goals. We have to do more, and we’ve recognized that.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
